HD-OPM Archive
Topics › Brain health & dementia

Only lipophilic statins like atorvastatin enter the brain; PCSK9 drugs and ezetimibe don't

Louis Nervegna · Oct 18, 2025 · ♥ 25 reactions · 10 comments · original Facebook post
Brain health & dementiaStatinsPCSK9, ezetimibe & newer drugs
AI summary & key facts

Louis explains the blood-brain barrier and cholesterol: the brain makes its own cholesterol separately from blood, so non-statin LDL drugs and hydrophilic statins like rosuvastatin have little brain effect. Lipophilic statins do enter the brain, with promising observational data against Alzheimer's, and a 20,000-person atorvastatin trial is under way. Two prior trials showed statins do not worsen existing Alzheimer's, and midlife high LDL is a leading modifiable dementia risk (2024 Lancet Commission, about 7% of US cases per Louis).

Hydrophilic statins like rosuvastatin don’t cross the blood brain barrier very well. So they have little effect on cholesterol production in the brain.

Other drugs like PCSK9 inhibitors, ezetimibe, bempedoic acid, etc. have ZERO effect on cholesterol production in the brain. They only affect cholesterol levels in the blood, which does not cross the blood brain barrier. The brain makes all its own cholesterol internally, completely separate from what’s in the blood. The blood brain barrier does not allow cholesterol in the blood to enter the brain:

↪ Hashtag-only image post on brain cholesterol, PCSK9 and dementia

So what about lipophilic statins like atorvastatin? These do get into the brain. They do cross the blood brain barrier. But there is promising research that shows these lipophilic statins may prevent Alzheimer’s:

↪ Statin use linked to 20% lower dementia and 32% lower Alzheimer's risk in meta-analysis

In fact, the research is so promising that there is now a giant 20,000 person randomized trial testing whether atorvastatin can prevent Alzheimer’s in older people. We should get the results in a few years:

↪ PREVENTABLE: atorvastatin 40 mg vs placebo up to 5 years in ~20,000 adults 75+

However we already know from two previous trials that lipophilic statins do not make existing Alzheimer’s worse (nor do they seem to help unfortunately):

↪ Two RCTs found statins neither helped nor harmed Alzheimer's disease progression

High LDL in midlife is now recognized as the biggest modifiable risk factor for dementia (2024 Lancet Commission Report). It is estimated to be responsible for 7% of dementia cases in the USA:

↪ Lancet Commission 2024: high LDL and hearing loss each account for 7% of dementia cases

↪ 2024 Lancet Commission: high LDL is the top modifiable dementia risk factor (7% of cases)

You can read past posts in the group on these topics by searching for the tags #ldldementiaHD and #statinsdementiaHD.


#bbbHD #braincholesterolHD #dementiaHD
#alzheimersHD #pcsk9HD #brainHD
#pcsk9dementiaHD #ldldementiaHD #statinsdementiaHD #atorvastatinHD #rosuvastatinHD #statinsHD #bempedoicacidHD #ezetimibeHD

Research cited

← newer: 2025 ESC/EAS update: where ezetimibe, bempedoic acid, PCSK9 older: A high CAC score mainly proxies dangerous soft plaque, so fo →